Xencor (NASDAQ:XNCR) SVP Celia Eckert Sells 1,492 Shares

by · The Cerbat Gem

Xencor, Inc. (NASDAQ:XNCR – Get Free Report) SVP Celia Eckert sold 1,492 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $11.90, for a total value of $17,754.80. Following the completion of the transaction, the senior vice president directly owned 81,929 shares of the company’s stock, valued at approximately $974,955.10. This trade represents a 1.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Xencor Price Performance

Shares of NASDAQ:XNCR traded up $0.72 during trading on Wednesday, reaching $12.74. The stock had a trading volume of 704,223 shares, compared to its average volume of 590,924. Xencor, Inc. has a 52 week low of $6.92 and a 52 week high of $18.69. The business’s 50-day moving average price is $12.96 and its 200 day moving average price is $12.91. The stock has a market capitalization of $934.35 million, a PE ratio of -10.27 and a beta of 0.95. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.25 and a quick ratio of 6.25.

Xencor (NASDAQ:XNCR – Get Free Report) last issued its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.55. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The company had revenue of $28.24 million during the quarter, compared to analysts’ expectations of $29.97 million. During the same quarter in the previous year, the company posted ($0.62) EPS. The business’s revenue for the quarter was down 46.6% compared to the same quarter last year. As a group, equities analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Primecap Management Co. CA raised its holdings in shares of Xencor by 1.4% during the third quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock valued at $125,218,000 after purchasing an additional 147,700 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Xencor by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock valued at $109,703,000 after purchasing an additional 61,692 shares in the last quarter. BVF Inc. IL boosted its holdings in shares of Xencor by 160.3% in the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after purchasing an additional 4,393,579 shares during the period. RTW Investments LP raised its position in Xencor by 8.9% in the 4th quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock worth $103,763,000 after purchasing an additional 556,407 shares during the period. Finally, State Street Corp boosted its holdings in Xencor by 22.7% during the 4th quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock valued at $69,006,000 after acquiring an additional 833,423 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on XNCR shares. JPMorgan Chase & Co. dropped their price target on Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Wedbush reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of Xencor in a research note on Thursday, November 6th. Cantor Fitzgerald raised their price target on shares of Xencor from $40.00 to $42.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Royal Bank Of Canada boosted their price objective on Xencor from $18.00 to $19.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, Truist Financial assumed coverage on Xencor in a report on Monday, November 24th. They issued a “buy” rating and a $29.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

View Our Latest Report on XNCR

About Xencor

(Get Free Report)

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

See Also